Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;22(12):171-182.
doi: 10.1007/s11882-022-01046-x. Epub 2022 Oct 29.

Cardiac Sarcoidosis: Current Approaches to Diagnosis and Management

Karen Flores Rosario  1 , Kyla Brezitski  1 , Kelly Arps  1 , Megan Milne  2 , Jayanth Doss  2 , Ravi Karra  3   4
Affiliations
Review

Cardiac Sarcoidosis: Current Approaches to Diagnosis and Management

Karen Flores Rosario et al. Curr Allergy Asthma Rep. 2022 Dec.

Abstract

Purpose of review: Cardiac sarcoidosis (CS) is an important cause of non-ischemic cardiomyopathy and has specific diagnostic and therapeutic considerations. With advances in imaging techniques and treatment approaches, the approach to monitoring disease progression and management of CS continues to evolve. The purpose of this review is to highlight advances in CS diagnosis and treatment and present a center's multidisciplinary approach to CS care.

Recent findings: In this review, we highlight advances in granuloma biology along with contemporary diagnostic approaches. Moreover, we expand on current targets of immunosuppression focused on granuloma biology and concurrent advances in the cardiovascular care of CS in light of recent guideline recommendations. Here, we review advances in the understanding of the sarcoidosis granuloma along with contemporary diagnostic and therapeutic considerations for CS. Additionally, we highlight knowledge gaps and areas for future research in CS treatment.

Keywords: Biomarkers; Cardiac sarcoidosis; Immunosuppression; Non-caseating granulomas.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Young RC Jr, Rachal RE, Cowan CL Jr. Sarcoidosis—the beginning: historical highlights of personalities and their accomplishments during the early years. J Natl Med Assoc. 1984;76(9):887.
    1. Rybicki BA, Major M, Popovich J Jr, Maliank MJ, lannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41. - DOI
    1. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227–40. - DOI
    1. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Pathol Int. 1993;43(7–8):372–6. - DOI
    1. •• Rosenthal DG, Parwani P, Murray TO, Petek BJ, Benn BS, De Marco T, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019;8(18):e010952. Study showing steroid-sparing agents are an effective maintenance therapy in patients with cardiac sarcoidosis after an initial response to steroids is achieved. - DOI

Publication types

LinkOut - more resources